$84.00
Manufacturer: Netherlands
Adult patients with diabetes type 2 diabetes drug Januvia shown to improve glycemic control in: as monotherapy when the patient’s condition is not properly controlled by diet and exercise alone and when Metformin cannot be used due to contraindications or intolerance; as a double oral therapy in combination with: Metformin when diet and exercise combined with Metformin alone do not provide adequate glycemic control; sulfonylurea when diet and exercise combined with the maximum tolerated dose of sulfonylurea alone do not provide adequate glycemic control and when Metformin cannot be used through contraindications or intolerance; an agonist of the gamma-receptor proliferation activator peroxisom (Ppary) (i.e., tiazolidindione), when the use of the Ppary agonist is appropriate and when diet and exercise in combination with the Ppary agonist alone do not provide adequate glycemic control;
Description
Januvia Composition
The active ingredient is sitagliptin (one coated tablet contains sitagliptin phosphate hydrate equivalent to 100 mg sitagliptin).
Excipients: microcrystalline cellulose, calcium hydrogen phosphate, croscarmellose sodium, magnesium stearate, sodium stearyl fumarate; tablet shell – dye Opadray® II beige.
Januvia Contraindications
hypersensitivity to the components of the drug;
type 1 diabetes mellitus;
diabetic ketoacidosis.
Mode of application
It is recommended to take Januvia 100 mg once a day as monotherapy or in combination with metformin and / or PPARγ agonist (eg thiazolidinedione).
When Januvia is prescribed in combination with a sulfonylurea or insulin, a lower dose of a sulfonylurea or insulin is considered to reduce the risk of hypoglycemia.
If a patient misses a medication, the dose should be taken as soon as possible after the patient remembers the missed medication. It is unacceptable to take a double dose of Januvia on the same day.
Januvia can be taken with or without food.
Januvia Application features
Pregnant
No controlled clinical trials of Januvia with the participation of pregnant women have been carried out, therefore it is not recommended for use during pregnancy. There is no data on the excretion of sitagliptin in breast milk, so the drug is not prescribed during lactation. Animal studies have shown reproductive toxicity when the drug is used in high doses. Animal data do not indicate a possible effect of sitagliptin treatment on male and female fertility. The potential risk to humans is unknown.
There are no data from human studies.
Children
The efficacy and safety of using the drug in patients under the age of 18 years has not been sufficiently studied, therefore, this drug should not be prescribed to this age group of patients.
Drivers
When driving vehicles or other mechanisms, it is recommended to be especially careful, given the possibility of adverse reactions from the nervous system (dizziness, drowsiness). Patients should be warned about the risk of hypoglycemia when using Januvia as part of a combination treatment.
Overdose
During clinical studies involving healthy volunteers, a single dose of 800 mg of Januvia was generally well tolerated. The minimum changes in the QTc interval, which are not considered clinically significant, were noted in one of the studies of the use of the drug “Januvia” at a dose of 800 mg per day. Doses greater than 800 mg per day have not been studied.
Recent Reviews